Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that President
and Chief Executive Officer Ron Cohen, M.D, has been elected as the
Chair of the Biotechnology Industry Organization (BIO) Board of
Directors for the 2015-2016 term. He will also serve as the Chairman of
the Health Section Governing Board.
“The biotech industry is among the most innovative in the world,
developing life-changing medicines that improve our health, agricultural
advances that help us feed an expanding global population, and cleaner,
more efficient energy that allows us to fuel our economy while
preserving our environment,” said Dr. Cohen. “It is a privilege to help
BIO continue to advance our member companies’ collective mission to
contribute these extraordinary advances to society.”
The BIO chair is a rotational position. Dr. Cohen will serve in this
role through June 2016, and is eligible for re-election for another
1-year term. He previously served as Chair of the Emerging Companies
Section Governing Board and Vice Chair of the Health Section Governing
Board of BIO.
“Ron Cohen has been an active member of the Board for many years and
will bring tremendous passion and a wealth of industry experience to
help drive continued growth of BIO and the overall industry,” said Jim
Greenwood, BIO President and CEO. “I look forward to working closely
with Ron and our newly-constituted Board of Directors in the years to
come.”
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders.
Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve
walking in patients with multiple sclerosis (MS), as demonstrated by an
increase in walking speed. The Company has one of the leading pipelines
in the industry of novel neurological therapies. Acorda is currently
developing a number of clinical and preclinical stage therapies. This
pipeline addresses a range of disorders including post-stroke walking
deficits, Parkinson’s disease, epilepsy, neuropathic pain, heart
failure, MS and spinal cord injury.
For more information, please visit the Company’s website at: www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including the ability to realize the benefits anticipated from the
Civitas transaction and to successfully integrate Civitas' operations
into our operations; our ability to successfully market and sell Ampyra
in the U.S.; third party payers (including governmental agencies) may
not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other acquired
or in-licensed programs; we may not be able to complete development of,
obtain regulatory approval for, or successfully market CVT-301, Plumiaz,
or any other products under development; we may need to raise additional
funds to finance our expanded operations and may not be able to do so on
acceptable terms; the occurrence of adverse safety events with our
products; delays in obtaining or failure to obtain regulatory approval
of or to successfully market Fampyra outside of the U.S. and our
dependence on our collaboration partner Biogen in connection therewith;
competition; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and, failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005150/en/
Copyright Business Wire 2015